AuraVax Therapeutics awarded contract from BARDA to evaluate NanoSTING platform as mucosal adjuvant for intranasal pandemic influenza vaccine
AuraVax Therapeutics, Inc., a company developing novel immunotherapies to prevent and treat respiratory pathogens, today announced it has been awarded a preclinical research contract with the Division ...
EuropaWire29d
AstraZeneca Presents New Data at IDWeek 2024, Showcasing Progress in Respiratory Disease Prevention and Vaccine Innovation
(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, ...